A sustainable house design to improve child health in rural Africa: a cluster-randomized controlled trial.

Here we provide support for the hypothesis that children can be protected from these diseases by improvements in house design.

在这里，我们为以下假设提供了支持：通过改善房屋设计，可以保护儿童免受这些疾病的侵害。

We designed a novel double-story house, called a Star Home, to provide an insect-proof, cleaner, cooler and smoke-free environment, with a reliable supply of water and sanitation.

我们设计了一种新颖的双层房屋，称为星型住宅，以提供一个防虫、更清洁、更凉爽且无烟的环境，同时确保有可靠的水源和卫生设施供应。

We conducted a cluster-randomized controlled trialwhere households with children under 13 years of age were randomly allocated (1:4.7) to living in 110 Star Homes or in 513 traditional mud and thatched-roofed houses.

我们进行了一项群组随机对照试验，将13岁以下儿童的家庭随机分配（1:4.7）到居住在110个星型住宅或513个传统泥屋和茅草屋顶房屋中。

The primary outcome of childhood malaria incidencewas met: after 3 years, children living in Star Homes had 44% less malaria (incidencerate ratio (IRR): 0.56 (95% confidence interval(CI): 0.43-0.72), P < 0.0001) compared to children living in traditional homes.

主要结果指标是儿童疟疾发病率：3年后，住在星级家园的儿童比住在传统家园的儿童疟疾发病率低44%（发病率比（IRR）：0.56（95%置信区间（CI）：0.43-0.72），P < 0.0001）。

Children in Star Homes had 30% less diarrhea (IRR: 0.70 (95% CI: 0.53-0.91), P = 0.0070) and 18% less ARIs (IRR: 0.82 (95% CI: 0.73-0.93), P = 0.0010) than children living in traditional homes.

住在星级家园的儿童比住在传统家园的儿童腹泻发病率低30%（发病率比（IRR）：0.70（95%置信区间（CI）：0.53-0.91），P = 0.0070），急性呼吸道感染（ARI）发病率低18%（发病率比（IRR）：0.82（95%置信区间（CI）：0.73-0.93），P = 0.0010）。

Children under 5 years of age living in Star Homes were also taller for their age than those living in traditional homes.

居住在星之家的5岁以下儿童的身高也比那些居住在传统房屋中的儿童更高。

Our house design is intended to inspire those working in the building sector and with local communities to develop innovative designs for healthier homes.

我们的房屋设计旨在激励建筑行业的从业者以及与当地社区合作的人们，开发出创新的健康住宅设计。

Major improvements in rural house design have the potential to make a substantial public health impact across hot, humid regions of Africa.

在非洲炎热湿润地区的农村房屋设计上的重大改进有可能对公共卫生产生重大影响。

ClinicalTrials.gov: NCT04529434 .

ClinicalTrials.gov: NCT04529434 .